ArticleJournal of medicinal chemistry2026
Identification of an Orally Efficacious Imidazo[4,5-
Bo Zhou, Leticia S Do Amaral, Emily K Bremers, Reagan S Haney, Lyric A Wardlaw, Emilio F Merino, Yuexin Li, Mairi Buchanan, Delphine Baud, Stephen Brand and 5 more
Abstract read
In one paragraphArticle in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Bo ZhouDepartment of Pharmaceutical Sciences, University of Illinois Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States.ORCID 0009-0001-5603-4221 Leticia S Do AmaralDepartment of Infectious Diseases University of Georgia, 120 Green Street, Athens, Georgia 30602, United States.ORCID 0000-0002-2861-216X Emily K BremersCenter for Tropical and Emerging Global Diseases, University of Georgia, 120 Green Street, Athens, Georgia 30602, United States.ORCID 0000-0002-9768-0211 Reagan S HaneyCenter for Tropical and Emerging Global Diseases, University of Georgia, 120 Green Street, Athens, Georgia 30602, United States.ORCID 0000-0002-2452-4103 Lyric A WardlawCenter for Tropical and Emerging Global Diseases, University of Georgia, 120 Green Street, Athens, Georgia 30602, United States.
Emilio F MerinoCenter for Tropical and Emerging Global Diseases, University of Georgia, 120 Green Street, Athens, Georgia 30602, United States.ORCID 0000-0002-5400-7377 Yuexin LiDepartment of Veterans Affairs Medical Center, Portland, Oregon 97239, United States.
Mairi BuchananBiological Chemistry and Drug Discovery, Faculty of Life Sciences, University of Dundee, Dundee DD1 4HN, U.K.
Stephen BrandMedicines for Malaria Venture, 1215 Geneva, Switzerland.
Marcus C S LeeBiological Chemistry and Drug Discovery, Faculty of Life Sciences, University of Dundee, Dundee DD1 4HN, U.K.
Maria B CasseraCenter for Tropical and Emerging Global Diseases, University of Georgia, 120 Green Street, Athens, Georgia 30602, United States.ORCID 0000-0001-6341-3169 Paul R CarlierDepartment of Pharmaceutical Sciences, University of Illinois Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States.ORCID 0000-0002-6683-285X Funding
Training in Tropical and Emerging Global Diseases - SupplementT32AI060546 · NIAID · UNIVERSITY OF GEORGIA (UGA) · PI Silvia N Moreno, Vasant Muralidharan · 2004 to 2026
$5.1MOptimization of antimalarials targeting multiple life stages of the parasiteR01AI157445 · NIAID · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI Paul R Carlier, Maria Belen Cassera · 2021 to 2026
$4.5MPREP at University of GeorgiaR25GM109435 · NIGMS · UNIVERSITY OF GEORGIA · PI DOLAN, ERIN L, KLONOWSKI, KIMBERLY D. · 2014 to 2024
$3.4MSecond-Generation Novel Liver Stage Active AntimalarialsR01AI158533 · NIAID · PORTLAND STATE UNIVERSITY · PI KELLY, JANE X, ROTH, ALISON ELIZABETH · 2021 to 2025
$3.3MUnderstanding Plasmodium falciparum's multidrug resistance protein through the characterization of a novel antimalarial class.F31AI181461 · NIAID · UNIVERSITY OF GEORGIA · PI BREMERS, EMILY KARA · 2024 to 2025
$94kNIAID NIH HHS F31 AI181461NIAID NIH HHS R01 AI157445NIAID NIH HHS R01 AI158533NIAID NIH HHS T32 AI060546NIGMS NIH HHS R25 GM109435
6 · The paper itselfAbstract
Due to the emergence of resistance to both artemisinin derivatives, and their partner drugs, new antimalarials are urgently needed. Ideally, new orally active antimalarials would not only engage new targets but also demonstrate a high barrier to resistance selection, and the ability to kill both proliferating rings and growth-arrested rings resulting from artemisinin exposure. In this report we disclose a novel antimalarial chemotype, the imidazo[4,5-
Indexed as
AntimalarialsDrug ResistanceImidazolesMalariaPlasmodium yoeliiPyridinesAdministration, OralAnimalsHumansMiceStructure-Activity RelationshipAntimalarialsImidazolesPyridines
Identifiers
PMID42045167
PMCPMC13224240
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390